Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Japan, April 13, 2006 - Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) has today announced that its EU subsidiary submitted a Marketing Authorization...
Read more about MAA Submission for Candin Antifungal Agent Micafungin in EU
Astellas Pharma Inc.("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) announced that Astellas today established a new active pharmaceutical ingredient (API) manufacturing...
Read more about Astellas Establishes New Subsidiary "Astellas Pharma Chemicals Co., Ltd."
Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) has decided to offer an early retirement program for its employees at its Doshomachi office and employees...
Follow us
